Status:
COMPLETED
Neurobehavior and Brain Connectivity in Post COVID-19 Patients
Lead Sponsor:
Consorci Sanitari de Terrassa
Collaborating Sponsors:
University of Barcelona
Universitat Politècnica de Catalunya
Conditions:
Post-COVID Syndrome
Eligibility:
All Genders
18-65 years
Brief Summary
COVID-19 neurological effects can generate long-term neurobehavioral dysfunction. Our main objective is to examine the impact of COVID-19 on neurobehavior and its relationship with illness severity. B...
Detailed Description
NAUTILUS is an observational, cross-sectional, and multicenter study. It will be performed at 22 public hospitals. Two groups of COVID-19 adults (Severe N=210, Moderate-mild N=210, WHO criteria) repor...
Eligibility Criteria
Inclusion
- PCS from SEVERE COVID-19 group
- Confirmed diagnosis of COVID-19 according to WHO interim with signs and symptoms of the severe disease during the acute phase
- Presence of cognitive complaints after COVID-19 diagnosis
- Participants have to be discharged from the hospital at least three months before inclusion
- Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki
Exclusion
- Participants have symptoms of delirium according to Delirium Rating Scale-revised 98
- Established diagnosis before COVID-19 disease of psychiatric, neurological, neurodevelopmental disorder or systemic pathologies are known to cause cognitive deficits
- Motor or sensory alterations that impede the neuropsychological examination
- Participants with a metal prosthesis (for MRI studies)
- Subjects suffering from claustrophobia or requiring sedation due to high anxiety (for MRI studies)
- PCS from MILD COVID-19 group
- Confirmed diagnosis of MILD COVID-19 according to WHO interim
- Presence of cognitive complaints after COVID-19 diagnosis
- Participants have to be diagnosed with COVID-19 at least three months before inclusion
- Accept to take part in the study and sign the informed consent according to the Declaration of Helsinki
Key Trial Info
Start Date :
October 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 15 2024
Estimated Enrollment :
630 Patients enrolled
Trial Details
Trial ID
NCT05307575
Start Date
October 1 2021
End Date
September 15 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Consorci Sanitari de Terrassa
Terrassa, Barcelona, Spain, 08227